vs

Side-by-side financial comparison of STEM, INC. (STEM) and Zymeworks Inc. (ZYME). Click either name above to swap in a different company.

STEM, INC. is the larger business by last-quarter revenue ($47.1M vs $27.6M, roughly 1.7× Zymeworks Inc.). STEM, INC. runs the higher net margin — -33.9% vs -71.0%, a 37.1% gap on every dollar of revenue. On growth, Zymeworks Inc. posted the faster year-over-year revenue change (72.6% vs -15.6%).

StemCells, Inc. is a public biopharmaceutical company headquartered in Newark, California, that is developing purified human neural stem cells (HuCNS-SCs) in the hopes of treating central nervous system disorders and paralysis. StemCells' HuCNS-SCs have the ability to differentiate into the three main types of cells found in the central nervous system: neurons, astrocytes and oligodendrocytes.

Zymeworks Inc. is a publicly held biotechnology company based in Vancouver, British Columbia, that develops protein therapeutics for the treatment of cancer as well as for autoimmune and inflammatory diseases. The products are based upon the company's molecular modeling software for optimizing protein structure. In 2014, Zymeworks raised $44 million across various funding rounds according to PitchBook, placing it among the top 10 HealthTech businesses in the world to raise the most capital th...

STEM vs ZYME — Head-to-Head

Bigger by revenue
STEM
STEM
1.7× larger
STEM
$47.1M
$27.6M
ZYME
Growing faster (revenue YoY)
ZYME
ZYME
+88.1% gap
ZYME
72.6%
-15.6%
STEM
Higher net margin
STEM
STEM
37.1% more per $
STEM
-33.9%
-71.0%
ZYME

Income Statement — Q4 FY2025 vs Q3 FY2025

Metric
STEM
STEM
ZYME
ZYME
Revenue
$47.1M
$27.6M
Net Profit
$-16.0M
$-19.6M
Gross Margin
48.9%
Operating Margin
-17.7%
-80.1%
Net Margin
-33.9%
-71.0%
Revenue YoY
-15.6%
72.6%
Net Profit YoY
68.8%
34.3%
EPS (diluted)
$-4.40
$-0.26

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
STEM
STEM
ZYME
ZYME
Q4 25
$47.1M
Q3 25
$38.2M
$27.6M
Q2 25
$38.4M
$48.7M
Q1 25
$32.5M
$27.1M
Q4 24
$55.8M
$31.0M
Q3 24
$29.3M
$16.0M
Q2 24
$34.0M
$19.2M
Q1 24
$25.5M
$10.0M
Net Profit
STEM
STEM
ZYME
ZYME
Q4 25
$-16.0M
Q3 25
$-23.8M
$-19.6M
Q2 25
$202.5M
$2.3M
Q1 25
$-25.0M
$-22.6M
Q4 24
$-51.1M
$-23.5M
Q3 24
$-148.3M
$-29.9M
Q2 24
$-582.3M
$-37.7M
Q1 24
$-72.3M
$-31.7M
Gross Margin
STEM
STEM
ZYME
ZYME
Q4 25
48.9%
Q3 25
35.5%
Q2 25
33.4%
Q1 25
32.4%
Q4 24
-4.4%
Q3 24
21.2%
Q2 24
27.6%
Q1 24
-95.0%
Operating Margin
STEM
STEM
ZYME
ZYME
Q4 25
-17.7%
Q3 25
-33.6%
-80.1%
Q2 25
-34.8%
-1.4%
Q1 25
-65.0%
-94.5%
Q4 24
-84.4%
-71.6%
Q3 24
-493.2%
-213.8%
Q2 24
-1705.5%
-222.9%
Q1 24
-267.0%
-376.9%
Net Margin
STEM
STEM
ZYME
ZYME
Q4 25
-33.9%
Q3 25
-62.2%
-71.0%
Q2 25
527.8%
4.8%
Q1 25
-76.9%
-83.5%
Q4 24
-91.6%
-75.8%
Q3 24
-506.3%
-186.6%
Q2 24
-1712.6%
-195.8%
Q1 24
-283.9%
-315.6%
EPS (diluted)
STEM
STEM
ZYME
ZYME
Q4 25
$-4.40
Q3 25
$-2.84
$-0.26
Q2 25
$-1.79
$0.03
Q1 25
$-0.15
$-0.30
Q4 24
$-15.29
$-0.32
Q3 24
$-18.24
$-0.39
Q2 24
$-71.81
$-0.49
Q1 24
$-0.46
$-0.42

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
STEM
STEM
ZYME
ZYME
Cash + ST InvestmentsLiquidity on hand
$48.9M
$64.8M
Total DebtLower is stronger
Stockholders' EquityBook value
$-249.4M
$320.1M
Total Assets
$308.9M
$397.3M
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
STEM
STEM
ZYME
ZYME
Q4 25
$48.9M
Q3 25
$43.1M
$64.8M
Q2 25
$40.8M
$98.3M
Q1 25
$58.6M
$76.2M
Q4 24
$56.3M
$66.1M
Q3 24
$75.4M
$122.4M
Q2 24
$89.6M
$71.0M
Q1 24
$112.8M
$114.8M
Stockholders' Equity
STEM
STEM
ZYME
ZYME
Q4 25
$-249.4M
Q3 25
$-235.7M
$320.1M
Q2 25
$-214.1M
$334.5M
Q1 25
$-417.5M
$325.0M
Q4 24
$-398.4M
$338.8M
Q3 24
$-344.1M
$367.0M
Q2 24
$-203.2M
$406.2M
Q1 24
$371.6M
$438.0M
Total Assets
STEM
STEM
ZYME
ZYME
Q4 25
$308.9M
Q3 25
$362.6M
$397.3M
Q2 25
$379.2M
$408.4M
Q1 25
$405.1M
$425.5M
Q4 24
$437.4M
$463.1M
Q3 24
$537.8M
$487.2M
Q2 24
$691.5M
$515.6M
Q1 24
$1.3B
$553.8M

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
STEM
STEM
ZYME
ZYME
Operating Cash FlowLast quarter
$8.2M
$-31.4M
Free Cash FlowOCF − Capex
$-31.8M
FCF MarginFCF / Revenue
-115.2%
Capex IntensityCapex / Revenue
1.5%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters
$-65.5M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
STEM
STEM
ZYME
ZYME
Q4 25
$8.2M
Q3 25
$11.4M
$-31.4M
Q2 25
$-21.3M
$12.1M
Q1 25
$8.5M
$-3.4M
Q4 24
$-14.7M
$-41.5M
Q3 24
$-9.4M
$-5.9M
Q2 24
$-11.9M
$-25.0M
Q1 24
$-621.0K
$-37.7M
Free Cash Flow
STEM
STEM
ZYME
ZYME
Q4 25
Q3 25
$-31.8M
Q2 25
$11.6M
Q1 25
$-3.4M
Q4 24
$-41.8M
Q3 24
$-6.8M
Q2 24
$-25.6M
Q1 24
$-37.9M
FCF Margin
STEM
STEM
ZYME
ZYME
Q4 25
Q3 25
-115.2%
Q2 25
23.7%
Q1 25
-12.6%
Q4 24
-134.8%
Q3 24
-42.4%
Q2 24
-133.0%
Q1 24
-377.5%
Capex Intensity
STEM
STEM
ZYME
ZYME
Q4 25
Q3 25
1.5%
Q2 25
1.1%
Q1 25
0.1%
Q4 24
1.0%
Q3 24
5.6%
Q2 24
3.1%
Q1 24
1.8%
Cash Conversion
STEM
STEM
ZYME
ZYME
Q4 25
Q3 25
Q2 25
-0.11×
5.21×
Q1 25
Q4 24
Q3 24
Q2 24
Q1 24

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons